ECS BOTANICS HOLDINGS LTD

ASX:ECSPharmaceuticals, Biotechnology & Life Sciences

1.60B shares on issueASX (delayed) · as of 28 July 2026$0.005price · delayed$9.6Mmarket cap · indicative

Dilution grade

Not rated — outstanding-options data is unreliable after the share consolidation

Cash runwayno data — not a quarterly (4C/5B) cash filer

Share-count growth (24m)no data — options data unreliable after consolidation

Raise cadence (24m)2 cash raises

Options & rights overhangomitted — option-line data cannot be adjusted for the share consolidation on record in the last 24 months

In-the-money supplyomitted — option-line data cannot be adjusted for the share consolidation on record in the last 24 months

Pending proposed issuesnone

ECS BOTANICS HOLDINGS LTD's ordinary share count grew 23.5% between December 2024 and July 2026 to 1.60B shares. The company raised capital twice in the 24-month window for total proceeds of A$3.9M, most recently a A$1.9M placement in November 2025. Options overhang is omitted because outstanding option-line data cannot be adjusted for the recent share consolidation. At the June 2026 quarter the company reported A$1.8M in available cash, representing 4.9 quarters of cover at its reported burn rate. No proposed securities issues (Appendix 3B) are currently pending.

AI-generated summary of this page's cited filings · updated 28 July 2026

—

Max option dilution · omitted

—

ITM option dilution

Raises · last 12 months

4.9 qtrs

Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue

Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.60B per ASX (delayed) (28 July 2026).

Cash runway

—

Cover not computed for the latest quarter.

$1.8M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.

Paid plan

Cash runway history

Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.

Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

Date	Form	Security	Total on issue after	Source
1 July 2026	3H · cancellation	ECS : ORDINARY FULLY PAID	1.60B	Appendix 3H
1 July 2026	2A · quoted issue	ECS : ORDINARY FULLY PAID	1.60B	Appendix 2A
3 Mar 2026	3H · cancellation	ECS : ORDINARY FULLY PAID	1.60B	Appendix 3H
29 Jan 2026	2A · quoted issue	ECS : ORDINARY FULLY PAID	1.60B	Appendix 2A
20 Jan 2026	3G · unquoted	ECS : ORDINARY FULLY PAID	1.60B	Appendix 3G

Paid plan

Full issuance history

Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).

Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

$1.9M

Placement

10 Nov 2025 COMPLETE

Paid plan

Full raise history

Issue price, discount, brokers, purpose and tranche detail for every raise on record.

Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

Options summary omitted. option-line data cannot be adjusted for the share consolidation on record in the last 24 months

Director dealings

Date	Director	Type	Shares	Options	Value	Source
1 July 2026	Mrs Nan Maree Schoerie	Sell	—	—	$15k	3Y notice
29 Jan 2026	Mrs Nan Maree Schoerie	Other	67	9	—	3Y notice
29 Jan 2026	Jeremy Philip King	Other	6	1	—	3Y notice